| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 8,149,015 | 5,882,498 | 18,441,079 | 23,838,244 |
| Short-term investments | 8,959,614 | 19,854,723 | 16,871,229 | 24,747,039 |
| Prepaid expenses | 1,223,534 | 504,890 | 3,712,311 | 1,263,812 |
| Other current assets | 234,806 | 852,036 | 900,175 | 733,423 |
| Total current assets | 18,566,969 | 27,094,147 | 39,924,794 | 50,582,518 |
| Property and equipment, net | 756,077 | 898,930 | 1,033,965 | 1,169,056 |
| Operating lease right-of-use asset | 57,781 | 266,646 | 311,620 | 355,427 |
| Other assets | 35,909 | 53,910 | 53,910 | 53,910 |
| Total assets | 19,416,736 | 28,313,633 | 41,324,289 | 52,160,911 |
| Accounts payable | 3,936,948 | 2,033,431 | 2,825,005 | 3,222,510 |
| Accrued payroll liabilities | 234,392 | 1,269,474 | 920,774 | 868,024 |
| Other current liabilities | 3,347,515 | 2,643,840 | 2,366,123 | 2,220,063 |
| Estimate for accrued legal contingencies and related expenses | 2,574,759 | 2,069,067 | 2,054,357 | 1,806,065 |
| Insurance premium loan payable | 250,338 | NaN | NaN | NaN |
| Operating lease liability, current portion | 60,980 | 189,647 | 201,638 | 195,046 |
| Total current liabilities | 10,404,932 | 8,205,459 | 8,367,897 | 8,311,708 |
| Operating lease liability, net of current portion | 0 | 83,999 | 120,207 | 172,494 |
| Total liabilities | 10,404,932 | 8,289,458 | 8,488,104 | 8,484,202 |
| Common stock, 0.001 par value 100,000,000 shares authorized at march31, 2026 and december31, 2025 35,126,884 and 33,378,139 shares issued and outstanding at march31, 2026 and december31, 2025, respectively | 35,128 | 33,379 | 30,989 | 30,988 |
| Additional paid-in-capital | 208,360,523 | 206,865,282 | 205,237,719 | 203,323,584 |
| Accumulated deficit | -199,383,847 | -186,874,486 | -172,432,523 | -159,677,863 |
| Total stockholders equity | 9,011,804 | 20,024,175 | 32,836,185 | 43,676,709 |
| Total liabilities and stockholders equity | 19,416,736 | 28,313,633 | 41,324,289 | 52,160,911 |
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)